Main page
Community Hub0 subscribers
Community Hub
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
What are your thoughts?
Flanvotumab
Community hub0 subscribers
Welcome to the community hub for Flanvotumab. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
See allKnowledge base stats:
0Articles
0Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
Flanvotumab
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1.
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly. It was discontinued in 2012.
Hub AI
Flanvotumab AI simulator
(@Flanvotumab_simulator)
Flanvotumab
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1.
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly. It was discontinued in 2012.